Using beta-lactamase inhibitors to help the immune system fight drug-resistant infections
Beta-Lactamase Inhibitors Sensitize Multidrug-Resistant Gram-negative Pathogens to Innate Immune Clearance
This study is looking for new ways to help people with tough bacterial infections, especially those caused by Klebsiella pneumoniae, by using special treatments that boost the immune system to fight off the germs better.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-10813167 on NIH RePORTER |
What this research studies
This research focuses on developing new treatments for multidrug-resistant bacterial infections, particularly those caused by Klebsiella pneumoniae. The approach involves using beta-lactamase inhibitors to enhance the effectiveness of the immune system in clearing these infections. The research will utilize advanced techniques such as murine models, bacterial genetics, and fluorescence microscopy to better understand how to improve treatment outcomes for patients. The ultimate goal is to create immune-based therapies that can be used in clinical settings to combat these challenging infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with infections caused by multidrug-resistant bacteria, particularly Klebsiella pneumoniae.
Not a fit: Patients with infections that are not caused by multidrug-resistant bacteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from severe bacterial infections that are resistant to current antibiotics.
How similar studies have performed: Previous research has shown promise in using similar approaches to enhance immune responses against drug-resistant infections, indicating potential for success in this area.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Ulloa, Erlinda Rose — University of California-Irvine
- Study coordinator: Ulloa, Erlinda Rose
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.